Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03296813 · ClinicalTrials.gov registry record · Phase 3
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,973
- Enrollment target
NCT03296813 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 2,973 participants.
The verdict
NCT03296813, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,973 participants
- Enrollment target
Study Summary
TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.
Interventions
- DRUG Furosemide
- DRUG Torsemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,973 participants |
| Start Date | 2018-07-11 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03296813
The ClinicalTrials.gov registry entry for NCT03296813 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,973 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Furosemide is the first listed.
NCT03296813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03296813 about?
NCT03296813 is a clinical study titled "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure". TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treat...
What is the current status of trial NCT03296813?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,973 participants. The study started on 2018-07-11. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT03296813?
The interventions under investigation include: Furosemide (DRUG), Torsemide (DRUG).
Who is sponsoring clinical trial NCT03296813?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.